VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Stock Valuation
Review Vertex Pharmaceuticals Incorporated (VRTX) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 32.13
- Price to book
- 6.16
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $99.02B
- Premium or discount
- 36.59%
- Market cap
- $135.24B
Vertex Pharmaceuticals Incorporated (VRTX) Stock Valuation research
The Vertex Pharmaceuticals Incorporated valuation page presents the available multiples, profitability measures and BTI fair-value context for VRTX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.